AVBP

ArriVent is a pre-revenue clinical-stage cancer drug developer whose entire value rests on one molecule, firmonertinib — an EGFR-selective TKI for uncommon-mutation NSCLC (exon 20 insertion, PACC). The financials are exactly what you'd expect: no revenue across FY2023–FY2025, a widening net loss of -$166M in FY2025 (vs -$80.5M and -$69.3M prior), -54.1% ROE, and -$161M of operating cash burn. R&D nearly doubled YoY (+94.1% to $153M) as two pivotal Phase 3 trials ramped. This is a cash-incineration story, and management is explicit in the risk factors that it 'expect[s] to incur significant losses for the foreseeable future' and 'may never achieve or sustain profitability,' and that it 'currently depend[s] significantly on the success of firmonertinib.'

What keeps this out of 'avoid' is the balance sheet and the quality of the lead asset. Liabilities are tiny ($25.9M) against $307M of equity (0.08x leverage), and while headline cash is only $45.5M, current assets total $333M — the difference is short-term investments, so true liquidity is far higher than the cash line suggests. Against ~$161M annual burn that implies roughly two years of runway before a raise is forced. The asset itself is partially de-risked: firmonertinib is already approved and commercialized in China by Allist, carries FDA Breakthrough Therapy and Orphan Drug designations, and has shown genuinely strong signal — 79% of FAVOUR exon-20 patients with ≥30% tumor reduction, and 16.0-month mPFS with 68.2% cORR in the FURTHER PACC cohort.